Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 18/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5627767 | 0.81 | PTGER1 (0.62) | PTGER1CYP2C9 | |
| SCHEMBL5459143 | 0.81 | CYP1A2 (0.45) | PTGER1MEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL5777870 | 0.74 | GRIN2D (0.41) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL5465606 | 0.71 | IRAK4 (0.51) | PTGER1MEN1KMT2ASMN1; SMN2CYP2C9 | |
| SCHEMBL5630033 | 0.70 | PTGER1 (0.61) | PTGER1CYP2C9 | |
| SCHEMBL5473535 | 0.70 | PTGER1 (0.61) | PTGER1CYP2C9 | |
| SCHEMBL5464626 | 0.69 | PTGER1 (0.42) | PTGER1CYP2C9 | |
| SCHEMBL5463067 | 0.68 | GPX4 (0.45) | PTGER1MEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL14125145 | 0.67 | GAA (0.56) | MEN1MAPK1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL5481296 | 0.67 | PTGER1 (0.66) | PTGER1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072906-A1 | Pyrrole compounds | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| US-20070072906-A1 | Pyrrole compounds | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| US-20070072906-A1 | Pyrrole compounds | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| EP-1697319-A1 | PYRROLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005054191-A1 | PYRROLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072906-A1 | Pyrrole compounds | PRMT9, EPOR, ADCYAP1R1 | PTGER1 224/4885MEN1 601/4885MAPK1 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.